Sontag Foundation Inc.

The Sontag Foundation is the largest private donor to primary brain cancer research in the United States, having granted over $65 million to date from its Ponte Vedra Beach, Florida headquarters. With $219.6 million in assets as of FY2024 — more than doubled after a $106.4 million contribution in FY2022 — the Foundation is entering a period of significantly expanded grantmaking capacity, even as it remains laser-focused on a single disease area.

Unlike most private foundations, Sontag does not accept unsolicited proposals in the traditional sense. All grantmaking flows through published Requests for Applications (RFAs) tied to specific programs. First-time applicants must understand this upfront: monitoring the foundation's website and mailing list for RFA announcements is the primary way to enter the pipeline. The grants page (sontagfoundation.org/grant-application-process/) is the authoritative source for active cycles.

The Foundation's giving philosophy centers on scientist development, not project funding. The flagship Distinguished Scientist Award ($750,000 over five years) is structured to support early-career researchers through the most vulnerable phase of independent lab building, with $150,000/year providing meaningful salary and research support. The Foundation explicitly evaluates the scientist's potential for career-defining impact, not just the merit of a single proposal. This distinction matters for how applications are framed.

Organizationally, the Foundation supports roughly two dozen institutions in its grantee portfolio, overwhelmingly academic medical centers and research universities: Brigham & Women's, Dana-Farber, Boston Children's Hospital, NYU, Yale, Emory, Stanford School of Medicine, Michigan, Minnesota, Weill Cornell, Johns Hopkins, and Massachusetts General are all multi-grant recipients. Massachusetts (18 tracked grants), New York (9), Texas (9), Florida (8), and California (8) are the leading grant states. Community Foundation of Northeast Florida ($6.75M over three grants) appears as the top-line recipient and represents the Foundation's local Florida philanthropic channel, distinct from the research grants.

For applicants: align your work with therapeutic acceleration, not just basic biology. The Foundation's vocabulary centers on cures, diagnostics, treatment innovation, and quality-of-life improvements. Frame the translational potential of your research explicitly.

The Sontag Foundation's grantmaking has grown steadily across a decade. Annual total giving rose from $3.41M (FY2014) to $4.44M (FY2020), $5.04M (FY2021), $8.57M (FY2022), and $9.19M (FY2023). Grants paid (direct disbursements) tracked at $5.65M in FY2023 and $6.09M in FY2022, with the difference reflecting multi-year award commitments recorded as total giving. With assets of $219.6M as of FY2024, standard payout calculations suggest annual giving capacity of $10–11M going forward.

Across 84 tracked grants totaling $15.5 million, the average grant is $184,753 and the median is $150,000, consistent with the DSA's $150,000 annual payment structure. The grant range runs from $1,000 (Central Brain Tumor Registry data subscriptions) to $750,000 (multi-year DSA commitments), with a reported maximum of $600,000 per single award per the Foundation's stated restrictions — the $750,000 DSA is structured as five separate $150,000 annual disbursements.

By program, the grant landscape breaks into clear tiers: - $450,000–$750,000: DSA multi-year totals — 10+ elite research institutions at this level including Yale ($712K), Brigham & Women's ($525K), Boston Children's ($487K), and peer institutions at $450K each - $300,000–$400,000: Society for Neuro-Oncology ($384K), Cornell, UT Southwestern, UMass Med School - $75,000–$120,000: Investigator grants to Rice, Caltech, Pittsburgh; mid-tier institutional grants - $10,000–$75,000: National Brain Tumor Society ($116K), Brain Tumor Network ($67K), Pediatric Brain Tumor Foundation ($50K), American Brain Tumor Association ($50K) - Under $15,000: Infrastructure and registries — Central Brain Tumor Registry of the USA ($15K), International Brain Tumor Alliance ($3K)

Geographically, Massachusetts receives the largest share by volume (18 grants), reflecting the concentration of elite medical institutions in the Boston area. Texas (9), New York (9), Florida (8), and California (8) follow. The Foundation has no stated geographic restriction on brain cancer research grants; institutional prestige and research quality drive selection.

The following table compares Sontag Foundation to similar-asset peers from the database and a key mission-aligned funder:

Among asset-comparable peers, the Sontag Foundation is uniquely mission-concentrated — 100% of its research grantmaking targets a single disease. The Swartz Foundation (neuroscience theory and computation) is the closest structural analog — both are family foundations with large endowments supporting a narrow scientific niche with multi-year career awards. Neither accepts cold proposals.

The Mark Foundation for Cancer Research is the most strategically relevant peer despite a smaller asset base; the two foundations co-funded a $4 million glioblastoma coalition in February 2026. For applicants, a Sontag relationship meaningfully strengthens credibility with the Mark Foundation and vice versa, and the overlapping scientific advisory networks mean your work will often be evaluated by shared reviewers. Researchers funded by one are credible candidates for the other's programs.

The 18-month period from late 2024 through March 2026 was among the Foundation's most active on record. In December 2025, three researchers received the 2025 Distinguished Scientist Award: John Liu (UCSF) studying glioblastoma treatment resistance mechanisms, Tyler Miller (Case Western Reserve) targeting immunotherapy outcomes, and Christina Tringides (Rice University) developing personalized treatment techniques. Rice University's Tringides is notable as a bioengineering-track scientist, reflecting the Foundation's expanding definition of relevant research disciplines.

In February 2026, the Foundation co-led a $4 million glioblastoma coalition with the Mark Foundation, National Brain Tumor Society, and three other funders. Five projects received awards — one three-year $3M Endeavor Award to a Broad Institute/Dana-Farber team (Rameen Beroukhim, William Kaelin Jr., Keith Ligon) and four $250,000 one-year ASPIRE Awards including projects at Brigham and Women's, Cleveland Clinic, and Harvard Medical School.

The Sontag Innovation Fund continued its medtech portfolio expansion in late 2025: Cordance Medical (focused ultrasound for blood-brain barrier opening) raised $8M in seed funding in November 2025, and AiM Medical Robotics (MRI-guided neurosurgery robotics) completed an $8.1M Series A in October 2025. Both represent the Foundation's bet on device and platform technologies that complement pharmaceutical approaches.

The 2026 DSA application cycle opened January 12, 2026 with a submission deadline of March 18, 2026 — making this an active open window at time of publication. Awards from this cycle will be announced in fall 2026.

Know your eligibility window before doing anything else. The DSA requires a first independent faculty appointment no earlier than March 1, 2017 and no later than January 1, 2022. This is non-negotiable. Researchers outside this window should pursue AACR-Sontag Fellowships (for postdocs) or Investigator Grants instead.

Frame the scientist, not just the science. The Foundation explicitly funds scientists with potential for career-defining impact. Open your application with a clear articulation of what distinguishes your scientific thinking — not just your publication record. The committee is asking: could this person change the field? That framing should drive your entire proposal narrative.

Five pages means five pages, no exceptions. The research proposal (including all figures) is limited to five pages. Experienced reviewers treat violations as a signal of poor judgment. Use the constraint strategically: fewer specific aims with stronger conceptual clarity will outperform dense, comprehensive proposals.

Reference letters are read by every committee member in full. This is explicitly stated by the Foundation. Your three referees — department chair or program leader, postdoctoral advisor or training mentor, and a professional colleague — must write substantively about scientific originality and independence, not just productivity metrics. Brief letters or letters focused on impact factors will hurt, not help.

Lean into translational relevance. The Foundation's language is consistently therapeutic — cures, treatment, patient outcomes, drug development. Even basic science proposals should explicitly articulate the pathway to clinical relevance. Phrases like "these findings could enable" are too vague; say specifically what therapeutic hypothesis your work advances.

For the Innovation Fund track: If you are building a company or technology platform, the venture philanthropy channel via the Innovation Fund is a separate path entirely. Emphasize IP position, competitive differentiation, and clinical development milestones — not academic publication records. The Fund has backed device companies (Cordance Medical, AiM Medical Robotics) alongside drug developers.

Contact Shandra Koler early. The Senior Program Officer (skoler@sontagfoundation.org, 904-273-8755) handles eligibility and application questions. Reaching out with a focused question before submitting is appropriate and demonstrates genuine engagement — this is a relationship-oriented foundation.